Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of aficamten (CK-3773274) in symptomatic obstructive hypertrophic cardiomyopathy
NL-OMON54001Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Primary endpoint: Change in peak oxygen uptake. Started Jan 2023; status: active, not recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON54001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54001.